We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DIASORIN MOLECULAR

DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App




Low-Cost Blood Test Enables Early Alzheimer’s Detection

By LabMedica International staff writers
Posted on 16 May 2025

Scientists have identified several reliable blood-based biomarkers for Alzheimer’s disease. More...

These proteins, including amyloid and tau, accumulate in the brain and blood as the disease progresses. A blood test detecting these proteins can help identify the disease at its earliest stages, which is crucial as treatment may prevent or delay cognitive decline. While some tests are available, they tend to be costly, require specialized equipment, and typically only detect a limited number of biomarkers at once. Now, researchers have developed a new blood test that can detect early signs of Alzheimer’s by measuring proteins associated with the condition. This test simultaneously identifies five key Alzheimer’s biomarkers, surpassing existing blood tests, and uses equipment that is widely available in many laboratories.

The test, developed by researchers from the Keck School of Medicine of USC (Los Angeles, CA, USA), is called the Penta-Plex Alzheimer’s Disease Capture Sandwich Immunoassay (5ADCSI). It utilizes xMAP® technology, a widely available system from biotechnology company Luminex (Austin, TX, USA). To create the 5ADCSI test, the researchers selected five biomarkers known to accumulate in Alzheimer’s disease: two forms of amyloid (Aβ40 and Aβ42), phosphorylated tau, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). The team developed a custom test that detects the presence of these biomarkers in blood samples using the xMAP® system. This technology uses tiny color-coded beads coated with antibodies specific to the biomarkers. When a blood sample is added, the biomarkers bind to the beads. Powerful imaging sensors then detect the color emitted by the beads to measure the biomarkers.

After developing the test, the researchers applied it to measure Alzheimer’s-associated biomarkers in 63 blood samples from three groups: 11 patients with Alzheimer’s disease, 17 patients with mild cognitive impairment (a precursor to Alzheimer’s), and 35 healthy individuals. The 5ADCSI test detected the highest levels of biomarkers in patients with Alzheimer’s disease, followed by those with mild cognitive impairment. A specific biomarker, p217Tau, showed a particularly strong correlation with the disease. The researchers also tested the same biomarkers in cerebrospinal fluid (CSF), which generally contains higher levels of Alzheimer’s-related proteins but is more difficult and costly to collect. They found moderate to strong correlations between the blood and CSF results, indicating that the blood test is sensitive enough for early detection of these proteins.

Originally developed as a research solution to a practical issue, the 5ADCSI test aims to offer a low-cost option for widespread Alzheimer’s screening. This could make it possible for annual screenings, similar to cholesterol and blood sugar tests, to detect patients who may benefit from medications or lifestyle changes, such as increased exercise, to slow or prevent Alzheimer’s. The team is now working on commercializing the technology and validating its effectiveness in clinical settings. Following the proof-of-concept study, published in the Journal of Alzheimer’s Disease, the researchers plan to test the accuracy of 5ADCSI with hundreds of patients at different stages of Alzheimer’s. The team envisions broad usage of the test, especially since it relies on affordable, widely available technology, even outside the U.S. Their long-term goal is to integrate 5ADCSI with genetic testing for the APOE4 gene variant, which is linked to Alzheimer’s disease, to offer individuals personalized insights into their risk for the condition.

“The biggest advantage is that our test is very cost-effective compared to other existing technologies, and it’s relatively easy to implement because many laboratories in universities, hospitals, and clinics are already using this technology,” said Ebrahim Zandi, PhD, associate professor of molecular microbiology and immunology at the Keck School of Medicine, who led the research. “In the 10 to 20 years Alzheimer’s takes to develop, proteins such as amyloid and tau are slowly building up. If we have an affordable blood test that detects those proteins early on, we can start interventions long before symptoms begin.”


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.